ReviewF1000prime reports2014
Advances in the diagnosis and treatment of sarcoidosis.
Review in F1000prime reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Use of 18F-FDG PET in assessing response to treatment in adults with pulmonary sarcoidosis: A systematic literature review.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Put Down the ACE: Low Clinical Utility for Angiotensin-Converting Enzyme Levels in Sarcoidosis: A Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2024Article
- Article
- Oral Granulomatous Disorders: A Diagnostic Insight.Cureus · 2024Review
- Cystic bronchiectasis in sarcoidosis.Clinical case reports · 2023Article
- Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis.Pulmonary therapy · 2023Article
- Article
- Performance of a Computational Phenotyping Algorithm for Sarcoidosis Using Diagnostic Codes in Electronic Medical Records: Case Validation Study From 2 Veterans Affairs Medical Centers.JMIR formative research · 2022Article
- Identification of a novel presumed cardiac sarcoidosis category for patients at high risk of disease.International journal of cardiology · 2021Article
- Molecular mechanism of action and pharmacokinetic properties of methotrexate.Molecular biology reports · 2020Review
- Pathogenetic mechanism of oral granulomatous diseases: An update.Journal of family medicine and primary care · 2020Review
- Cardiac sarcoidosis in a patient with testicular seminoma.BMJ case reports · 2019Article
- Application of the modified Zajicek criteria to diagnose probable spinal cord neurosarcoidosis.Clinical case reports · 2018Article
- A rare presentation of pulmonary sarcoidosis as a solitary lung mass: a case report.Journal of medical case reports · 2018Article
- The Utility ofBioMed research international · 2018Article
- Remission of a long-lasting sarcoidosis after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.JAAD case reports · 2016Article
- Trouble Spotted in the Liver!Digestive diseases and sciences · 2016Article
- Successful treatment of refractory midgut bleeding with ocreotide and corticosteroids in a dialysis patient with suspected sarcoidosis.BMJ case reports · 2016Article
- Sarcoidosis with prevalent and severe joint localization: a case report.Multidisciplinary respiratory medicine · 2016Article
- Sarcoidosis: a diagnostic challenge in atypical radiologic findings of unilateral lymphadenopathy.Oxford medical case reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This manuscript outlines recent advances in the diagnosis and treatment of sarcoidosis. The diagnosis of sarcoidosis can occasionally be made on clinical grounds without a confirmatory biopsy when very specific clinical findings are present. Otherwise, the diagnosis requires histologic evidence of granulomatous inflammation, exclusion of alternative causes, and evidence of systemic disease. Because there is no available diagnostic test for sarcoidosis, the diagnosis is never completely secure. Instruments have been developed to establish the presence of sarcoidosis in a second organ and hence establish the systemic nature of the disease. Corticosteroids remain the drug of choice for the treatment of sarcoidosis. Additional sarcoidosis medications are most commonly used as corticosteroid-sparing agents. Recent clinical sarcoidosis drug trials have exposed important issues that may confound trial results, including selecting patients with active disease, identifying study drug effects in patients receiving concomitant corticosteroids, and establishing proper study endpoints.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.